BioCentury
ARTICLE | Company News

BMS, JNJ in deal for Factor XIa inhibitor

April 20, 2018 5:22 PM UTC

Bristol-Myers Squibb Co. (NYSE:BMY) and the Janssen Pharmaceuticals Inc. unit of Johnson & Johnson (NYSE:JNJ) partnered to develop and commercialize Factor XIa inhibitors, including BMS-986177.

BMS will receive an undisclosed upfront payment and is eligible for milestones. The companies will share costs and profits...

BCIQ Target Profiles

Factor XIa